Interferon Potency Assay via Wnt Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods to assess the biological activity and potency of rSIFN-co and other test interferons to ensure quality control and consistency, particularly in distinguishing them from commercially available interferons and determining their effectiveness in inhibiting cancer cell growth and related activities.
Innovation Solution
A method involving the comparison of test interferons with rSIFN-co through specific biological activities such as inhibition of cancer cell growth, viability, migration, beta-catenin/TCF transcriptional activity, and expression of certain genes, using tumor-bearing animal models and cancer cell lines to establish substantial equivalence and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rSIFN-co is used to inhibit cancer cell growth and migration, then therapeutic effectiveness is improved, but the complexity of assessing its potency and equivalence increases
Solution Approach 1:
The patent segments the assessment of interferon potency into multiple independent biological activity tests: (a) inhibition of cancer cell growth, (b) inhibition of cancer cell migration, (c) inhibition of pseudopod formation, (d) inhibition of beta-catenin/TCF transcriptional activity, (e) down-regulation of Wnt-related receptors, and (f) up-regulation of tumor suppressor genes. Each segment can be performed separately to evaluate specific aspects of interferon activity.
Solution Approach 2:
The patent establishes a universal assay system that can evaluate multiple biological activities of interferons using common cell lines (such as A549 lung cancer cells, SW620 colon cancer cells) and standardized protocols. This multi-functional assay platform allows simultaneous assessment of anti-proliferative, anti-migratory, and gene expression effects.
2Measurement precision
If multiple biological activities are tested to establish substantial equivalence, then measurement precision is improved, but the time and resources required increase
Solution Approach 1:
The patent employs preliminary action by first screening interferons for their ability to inhibit cancer cell growth and migration as primary endpoints. Only interferons that demonstrate significant activity in these preliminary tests proceed to more detailed assessments of gene expression changes and beta-catenin/TCF activity, thereby streamlining the overall assessment timeline.
Solution Approach 2:
The patent allows for partial assessment where testing all six biological activities is not always required. Depending on the specific application and regulatory requirements, a subset of activities (such as just growth inhibition and migration inhibition) can be performed to establish sufficient potency equivalence, reducing time and resource investment while maintaining adequate measurement precision.
Data Source
AI summary
The invention provides novel methods of determining or comparing potency of a test interferon relative to rSIFN-co (an interferon having therapeutic effects on solid tumors); methods of establishing substantial equivalence between a test interferon and rSIFN-co; methods for down-regulation of expression of Wnt-related receptors or co-receptors, such as LRP6/FZD6; down-regulation of expression of Wnt-related target genes, such as, Axin2, CD24, Survivin and/or ID2; inhibition of beta-catenin/TCF transcriptional activities; suppression of expression of beta-catenin; up-regulation of tumor suppressor genes, such as DKK-3, BATF2 and/or KLF4; inhibition of tumor cell viability in vitro; inhibition of tumor growth and metastases in vivo; inhibition of tumor cell migration, pseudopod formation, and colony formation in vitro; as well as methods for determining potency of a test interferon, kits for determination of such methods, and an interferon or an interferon substitute having said activities.